Colgate‑Palmolive Company reported its fourth‑quarter and full‑year 2025 results, posting net sales of $5.23 billion, a 5.8% year‑over‑year increase. The company recorded a GAAP diluted earnings per share of –$0.05, driven by a $794 million goodwill and intangible asset impairment related to its skin‑health business. Base‑business diluted EPS, which excludes the impairment, rose to $0.95, beating analyst expectations of $0.91–$0.94 and reflecting strong underlying profitability.
Revenue growth was led by a 2.2% increase in organic sales and a 23% jump in Hill’s Pet Nutrition sales, the largest contributor to the quarter’s top‑line momentum. Oral Care and Personal Care segments also delivered solid performance, while Home Care maintained steady sales, offsetting modest headwinds in legacy categories. The mix shift toward higher‑margin pet nutrition and oral care helped sustain revenue growth despite broader market softness.
Gross margin remained near 60%, a level the company attributes to disciplined pricing and effective cost management. Even with raw‑material inflation of roughly 600 basis points, the firm’s pricing power and scale allowed it to preserve margin. The 23% growth in pet nutrition, driven by strong demand in emerging markets, further bolstered the margin profile.
CEO Noel Wallace highlighted the company’s “accelerated growth momentum on both the top and bottom lines” and praised the resilience of its core businesses. He noted that “net sales and organic sales grew in every category during the quarter, led by strength in oral care and pet nutrition, excluding private label.” Management reiterated its 2030 strategy, emphasizing premium‑focused growth, science‑based innovation, and omni‑channel demand generation. Guidance for 2026 projects net sales growth of 2‑6% and organic sales growth of 1‑4%, with expectations of margin expansion as pricing discipline continues.
The $794 million impairment charge reflects a strategic reassessment of the skin‑health portfolio, which had underperformed relative to expectations. While the write‑down created a GAAP loss, it does not affect the company’s core operating performance, as evidenced by the robust base‑business EPS and margin maintenance. The charge underscores a shift away from legacy skin‑health assets toward higher‑growth segments such as pet nutrition and oral care.
Investors responded positively to the results, noting the earnings beat and the company’s clear guidance for 2026. Analysts highlighted the firm’s ability to sustain margin and revenue growth amid inflationary pressures, reinforcing confidence in its long‑term strategy.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.